On June 3, 2022 Hackensack Meridian John Theurer Cancer Center investigators participated in the large phase III multicenter SHINE study, which reported that using the drug ibrutinib (Imbruvica) in combination with standard bendamustine and rituximab (BR) therapy as initial treatment for mantle cell lymphoma (MCL) slowed disease growth by 52% in older people newly diagnosed with the disease (Press release, Hackensack Meridian Health, JUN 3, 2022, View Source [SID1234615551]). The treatment could become the new standard of care for older people with MCL, who may not be able to tolerate more intensive treatment regimens. The study was published in the New England Journal of Medicine on June 3, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The field of mantle cell lymphoma treatment continues to evolve. The standard of care for elderly patients — who account for more than half of all people diagnosed with mantle cell lymphoma and who are not eligible for high-dose therapy upfront — has most frequently been chemoimmunotherapy with bendamustine and rituximab. Over time, however, most patients relapse," explained Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center, who led the center’s participation in the SHINE study. "Ibrutinib was the first inhibitor of the BTK protein approved for MCL, and it has been a game changer for patients with relapsed or persistent disease. Logically, the next step was to bring it to the frontline setting, which was the subject of the SHINE clinical trial."
In this study, previously untreated MCL patients aged 65 and older were randomly assigned to receive six cycles of BR with either ibrutinib (261 patients) or a placebo (262 patients). Patients who responded to treatment received up to 12 additional doses of rituximab as maintenance therapy. Researchers compared progression-free survival (PFS, the time it took for the cancer to continue growing) between the two groups.
Adding ibrutinib to BR dramatically improved the outcome. After a median follow-up of 7 years, PFS was 6.7 years in the BR+ibrutinib arm versus 4.4 years for the BR+placebo group. Concluded Dr. Goy, "This is highly significant and could easily translate into BR+ibrutinib becoming the next standard of care."